PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
Abstract IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares the same RNA sequence as IONIS‐FXIRX but contain...
Enregistré dans:
Auteurs principaux: | Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro
par: Y. Shi, et autres
Publié: (2021) -
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
par: Niels Grote Beverborg, et autres
Publié: (2021) -
Tritium labeling of antisense oligonucleotides via different conjugation agents
par: Martin R. Edelmann, et autres
Publié: (2021) -
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
par: James S. Novak, et autres
Publié: (2017) -
Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
par: Kristin A. Ham, et autres
Publié: (2021)